About XOS (PreticX)
Xylooligosaccharides (XOS) are a prebiotic fiber built on a xylose backbone — chemically distinct from inulin-type fructans (FOS/oligofructose), which are fructose-based — branded as PreticX and derived mainly from corn cob. The defining feature is potency at low doses: human RCTs show a bifidogenic effect at 1-2.8 g/day, far below the 2.5-10 g/day needed for inulin/FOS, with less gas and bloating. The prebiotic/bifidogenic effect (a microbiome surrogate endpoint) is consistently demonstrated, but hard clinical-outcome data is thin or null — a prediabetic RCT at 1 g/day shifted gut microbiota yet found no significant effect on glucose, body composition, triglycerides, or satiety hormones. Much of the broader literature is animal rather than human. No established RDA/UL.
What XOS (PreticX) supports
- Increases beneficial Bifidobacteria at low doses (1-2.8 g/day)
- Prebiotic fiber that feeds the gut microbiome with less gas than inulin/FOS
How much XOS (PreticX) to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1000–4000
mg
Bifidogenic dose-response from human RCTs: Finegold 2014 (n=32 healthy) showed significant dose-dependent Bifidobacterium increases at 1.4 and 2.8 g/day over 8 weeks; a prediabetic/healthy RCT (n=29) used 1 g/day. Effective at far lower doses than inulin-type fructans (2.5-10 g/day). Upper bound ~4 g/day reflects the practical studied ceiling before GI tolerance limits intake.
Clinical evidence
Limited clinical evidence. Two small human RCTs (n=29-32) consistently show a dose-dependent bifidogenic effect at 1-2.8 g/day, but that is a microbiome surrogate endpoint — no meta-analyses on hard clinical outcomes exist and the one metabolic RCT was essentially null. Graded low: real but preliminary, small-sample, and microbiome-only.
NIH Fact Sheet